ホーム>>Signaling Pathways>> Apoptosis>> p53>>Pifithrin-β

Pifithrin-β (Synonyms: PFTμ, 2Phenylethynesulfonamide)

カタログ番号GC17262

ピフィスリン-β (PFT β) は、IC50 が 23 μM の強力な p53 阻害剤です。

Products are for research use only. Not for human use. We do not sell to patients.

Pifithrin-β 化学構造

Cas No.: 60477-34-1

サイズ 価格 在庫数
5mg
$40.00
Please Inquire
10mg
$61.00
Please Inquire
50mg
$281.00
Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com


顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Pifithrin-β (PFT β) is a potent p53 inhibitor with an IC50 of 23 μM.

Pifithrin-α, an inhibitor of the p53 protein, is regarded as a lead compound for cancer and neurodegenerative disease therapy. Pifithrin-α is very unstable in culture medium and rapidly converts to its condensation product pifithrin-β (PFT β), the N-acetyl derivative[2]. After 24 h, the viability assay shows that the pretreatments with 1 and 10 μM pifithrin-β exerts neuroprotective effects[3].

References:
[1]. Christodoulou MS, et al. Synthesis and biological evaluation of imidazolo[2,1-b]benzothiazole derivatives, as potential p53 inhibitors. Bioorg Med Chem. 2011 Mar 1;19(5):1649-57.
[2]. Fernández-Cruz ML, et al. Biological and chemical studies on aryl hydrocarbon receptor induction by the p53 inhibitor pifithrin-α and its condensation product pifithrin-β. Life Sci. 2011 Apr 25;88(17-18):774-83.
[3]. Da Pozzo E, et al. p53 functional inhibitors behaving like pifithrin-β counteract the Alzheimer peptide non-β-amyloid component effects in human SH-SY5Y cells. ACS Chem Neurosci. 2014 May 21;5(5):390-9.

レビュー

Review for Pifithrin-β

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Pifithrin-β

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.